Tekla Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Tekla Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300,000	Closed	-$3.15M	–	182
2022 Q4	$3.15M	Hold	300,000	–	–	0.12%	96
2022 Q3	$2.39M	Buy	+300,000	New	+$2.12M	0.1%	109
2022 Q2	–	Sell	-250,000	Closed	-$2.77M	–	178
2022 Q1	$2.77M	Hold	250,000	–	–	0.1%	114
2021 Q4	$2.47M	Hold	250,000	–	–	0.08%	124
2021 Q3	$2.47M	Hold	250,000	–	–	0.08%	132
2021 Q2	$2.58M	Hold	250,000	–	–	0.08%	147
2021 Q1	$2.56M	Hold	250,000	–	–	0.09%	152
2020 Q4	$2.71M	Buy	+250,000	New	+$2.65M	0.1%	146

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tekla Capital Management's MLTX Position: Q1 2023 in Review

Tekla Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2023, closing a stake of 300,000 shares — an estimated $3.15M sold.

Tekla Capital Management first reported a position in MLTX in Q4 2020 and held it in 8 quarters. The position peaked at $3.15M in Q4 2022. 43 funds tracked by Wall St. Rank hold MLTX as of Q1 2023.

Tekla Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2023 after selling out during the quarter.
Tekla Capital Management sold 300,000 MoonLake Immunotherapeutics shares in Q1 2023, an estimated $3.15M.
Tekla Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 8 quarters.
Tekla Capital Management's MoonLake Immunotherapeutics position peaked at $3.15M in Q4 2022.
43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2023.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.